findmyKOL
Clinical trialNCT02089724UnknownObservational

Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease

SponsorGroupe Hospitalier Pitie-SalpetriereEnrollment20Erdheim-Chester Disease
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

France
  • Ap-Hp, Groupe Hospitalier Pitié-Salpêtrière

    Paris, France

    Fleur Cohen Aubart, MD, PhDJulien Haroche, MD, PhDZahir Amoura, MD, MSc
    Recruiting
United States
  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

    Eli L. Diamond, MD, PhDOmar Abdel-Wahab, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Mar 2014
Primary completion
31 Dec 2016
Completion
30 Apr 2019
Last update posted
28 Oct 2016
Registered enrollment
20
Registry id
NCT02089724
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.